<DOC>
	<DOCNO>NCT02608112</DOCNO>
	<brief_summary>This multicenter , prospective , non-interventional study design obtain accurate estimation drug retention rate Tocilizumab ( TCZ ) Subcutaneously ( SC ) real-world condition participant moderate severe rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>Study Describe Real World Drug Retention Rate Tocilizumab One Year</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Participants least 18 year old Participants moderate severe RA previously treat TCZ ( Intravenous [ IV ] SC ) rheumatologists decided initiate TCZ SC treatment monotherapy combination another conventional synthetic disease modify antirheumatic drug ( csDMARD ) Participants take part clinical trial RA time inclusion Participants contraindication TCZ SC therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>